Longer-term data bolster Nektar Therapeutics’ bempegaldesleukin, but things haven’t changed that much since its last disappointment.
A mid-stage study of enfortumab illustrates the relevance of nectin-4 in urothelial bladder cancer, and is hailed by experts as registrational.
The keenly awaited study of Lynparza in pancreatic cancer maintenance fails to show much beyond its headline primary endpoint of progression-free survival.
A first-line Keytruda study is nominally positive, but numerous questions remain before approval can be assured.
Anaptysbio’s etokimab needs to beat Dupixent, while Retrophin takes aims at an underserved rare disease.
Approvals for new uses of old drugs should far outweigh nods for novel projects in June.
Merck & Co faces two US FDA decisions in June, and neither is an obvious guarantee of success.
Biogen needs a win with its Tecfidera follow-on, while Kalvista hopes to make HAE where Biocryst failed.
Expectations are low for a three-year update on the group’s haemophilia A gene therapy, and Biomarin’s rivals could capitalise on any slip-up.